A double-blind study of the effects of MEPARTRICIN (cas 11121-32-7) in the treatment of obstruction due to benign prostatic hyperplasia
-
Add time:07/21/2019 Source:sciencedirect.com
A double-blind, randomized, comparative study of MEPARTRICIN (cas 11121-32-7) (SPA-S-160) and placebo was performed on 36 patients who complained of obstructive symptomatology caused by prostatic hypertrophy. Treatment was continued for 60 days at a dose of 150,000 IU/d (three capsules/d) of active substance. All patients underwent full urodynamic investigation consisting of pressure-flow studies before and after treatment. The final results of our study showed that 50% of the patients treated with mepartricin had an improvement in micturitional performance.
We also recommend Trading Suppliers and Manufacturers of MEPARTRICIN (cas 11121-32-7). Pls Click Website Link as below: cas 11121-32-7 suppliers
Prev:Role of MEPARTRICIN (cas 11121-32-7) in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized prospective placebo-controlled trial
Next:Characterization of Phytochrome (cas 11121-56-5) C functions in the control of de-etiolation and agronomic traits in rice) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Role of MEPARTRICIN (cas 11121-32-7) in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized prospective placebo-controlled trial07/19/2019
- Effects of MEPARTRICIN (cas 11121-32-7) on estradiol and testosterone serum levels and on prostatic estrogen, androgen and adrenergic receptor concentrations in adult rats07/18/2019